Immunostimulants drugs for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 hospitalized meta-analysis
Baldeon SRCTN85216856		RCT	convalescent plasma treatment	placebo	COVID 19 hospitalized	some concern	63/95	inconclusive
ITAC NCT04546581		RCT	neutralizing antibody	placebo	COVID 19 hospitalized	some concern	301/292	inconclusive	inconclusive 6 % increase in clinical improvement,clinical improvement (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias trial did not meet its endpoints (press release)
ASCOT NCT04483960		RCT	convalescent plasma treatment	standard of care	COVID 19 hospitalized	low	15/18	inconclusive
Bennett-Guerrero NCT04344535		RCT	convalescent plasma treatment	placebo	COVID 19 hospitalized	some concern	59/15	inconclusive
CCAP-2 NCT04345289		RCT	convalescent plasma treatment	placebo	COVID 19 hospitalized	low	98/46	inconclusive
Co-CLARITY NCT04567173		RCT	convalescent plasma treatment	standard of care	COVID 19 hospitalized	low	13/12	inconclusive
CONCOR-1 NCT04348656		RCT	convalescent plasma treatment	standard of care	COVID 19 hospitalized	some concern	625/313	safety concern	inconclusive 16 % increase in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias statistically significant 27 % increase in serious adverse events with a moderate degree of certainty due to some concern in risk of bias
CONTAIN COVID-19 NCT04364737		RCT	convalescent plasma treatment	placebo	COVID 19 hospitalized	some concern	468/473	inconclusive	inconclusive 6 % decrease in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
COP-COVID-19 NCT04358783		RCT	convalescent plasma treatment	standard of care	COVID 19 hospitalized	some concern	20/11	inconclusive
DAWN-Plasma NCT04429854		RCT	convalescent plasma treatment	standard of care	COVID 19 hospitalized	some concern	320/163	inconclusive
Holm K NCT04600440		RCT	convalescent plasma treatment	standard of care	COVID 19 hospitalized	some concern	17/14	inconclusive
Kirenga NCT04542941		RCT	convalescent plasma treatment	standard of care	COVID 19 hospitalized	some concern	67/69	inconclusive
Menichetti NCT04716556		RCT	convalescent plasma treatment	standard of care	COVID 19 hospitalized	some concern	241/246	inconclusive	inconclusive 12 % decrease in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
NCT04385199 NCT04385199		RCT	convalescent plasma treatment	standard of care	COVID 19 hospitalized	low	20/10	inconclusive
NCT04397757 NCT04397757		RCT	convalescent plasma treatment	standard of care	COVID 19 hospitalized	some concern	41/39	suggested	suggested 85 % decrease in deaths,death D28 with a moderate degree of certainty due to some concern in risk of bias
NCT04403477 (two doses) NCT04403477		RCT	convalescent plasma treatment	standard of care	COVID 19 hospitalized	low	40/20	inconclusive
NCT04442191 NCT04442191		RCT	convalescent plasma treatment	placebo	COVID 19 hospitalized	low	8/6	inconclusive
NCT04528368 NCT04528368		RCT	convalescent plasma treatment	standard of care	COVID 19 hospitalized	low	9/8	inconclusive
PC/COVID-19 NCT04366245		RCT	convalescent plasma treatment	standard of care	COVID 19 hospitalized	low	38/36	inconclusive
PERUCONPLASMA NCT04497324		RCT	convalescent plasma treatment	standard of care	COVID 19 hospitalized	low	12/13	inconclusive
RECOVERY (plasma) NCT04381936		RCT	convalescent plasma treatment	standard of care	COVID 19 hospitalized	some concern	5795/5763	inconclusive	inconclusive 0 % increase in deaths,death D28 (PE) with a moderate degree of certainty due to some concern in risk of bias
Balcells NCT04375098		RCT	Early convalescent plasma.	Deferred Convalescent plasma	COVID 19 hospitalized	low	28/30	inconclusive	inconclusive 33 % decrease in death or ventilation (PE) with a high degree of certainty due to low risk of bias
ConCOVID (Gharbharan et al.) NCT04342182		RCT	convalescent plasma treatment	standard of care	COVID 19 hospitalized	some concern	43/43	inconclusive	inconclusive 5 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
CONFIDENT NCT04558476		RCT	convalescent plasma treatment	standard of care	COVID 19 hospitalized	low	150/151	inconclusive
ConPlas-19 NCT04345523		RCT	convalescent plasma treatment	standard of care	COVID 19 hospitalized	some concern	179/171	inconclusive	inconclusive 6 % decrease in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
COPLA-II trial NCT04425915		RCT	convalescent plasma treatment	standard of care	COVID 19 hospitalized	some concern	200/200	suggested	suggested 42 % decrease in mechanical ventilation with a moderate degree of certainty due to some concern in risk of bias
Sakoulas NCT04411667		RCT	immunoglobulin therapy	standard of care	COVID 19 hospitalized	some concern	17/17	inconclusive	inconclusive 81 % decrease in mechanical ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
Salman NCT04530370		RCT	convalescent plasma treatment	standard of care	COVID 19 hospitalized	some concern	15/15	inconclusive
COVID 19 all comers meta-analysis
LIFESAVER NCT04374526		RCT	convalescent plasma treatment	standard of care	COVID 19 all comers	low	4/8	inconclusive
COVID-19 mild to moderate meta-analysis
Libster NCT04479163		RCT	convalescent plasma treatment	placebo	COVID-19 mild to moderate	low	80/80	conclusif	demonstrated 48 % decrease in clinical deterioration (PE) with a high degree of certainty due to low risk of bias
COVID-19 severe or critically meta-analysis
CAPSID NCT04433910		RCT	convalescent plasma treatment	standard of care	COVID-19 severe or critically	some concern	53/52	inconclusive	inconclusive 58 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
CP-COVID-19 NCT04332835		RCT	convalescent plasma treatment	standard of care	COVID-19 severe or critically	some concern	49/51	inconclusive	inconclusive 12 % increase in viral clearance (PE) with a moderate degree of certainty due to some concern in risk of bias
O’Donnell NCT04359810		RCT	convalescent plasma treatment	placebo	COVID-19 severe or critically	low	150/73	inconclusive	inconclusive 38 % increase in clinical improvement (28-day) (PE) with a high degree of certainty due to low risk of bias
Pouladzadeh IRCT20200310046736N1		RCT	convalescent plasma treatment	standard of care	COVID-19 severe or critically	some concern	31/31	suggested	suggested 6.3-fold increase in clinical improvement,clinical improvement (28-day) with a moderate degree of certainty due to some concern in risk of bias
Raman CTRI/2020/06/026222		RCT	immunoglobulin therapy	standard of care	COVID-19 severe or critically	some concern	50/50	suggested	suggested 35.4-fold increase in viral clearance ,viral clearance by day 14 with a moderate degree of certainty due to some concern in risk of bias
RECOVER EudCT 2020-001632-10		RCT	convalescent plasma treatment	standard of care	COVID-19 severe or critically	low	43/47	inconclusive
REMAP-CAP (plasma) NCT02735707		RCT	convalescent plasma treatment	standard of care	COVID-19 severe or critically	low	1095/916	safety concern	statistically significant 1.3-fold increase in serious adverse events with a high degree of certainty due to low risk of bias
Sekine (PLACOVID) NCT04547660		RCT	convalescent plasma treatment	standard of care	COVID-19 severe or critically	some concern	80/80	inconclusive	inconclusive 6 % decrease in clinical improvement,clinical improvement (28-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
AlQahtani NCT04356534		RCT	convalescent plasma treatment	standard of care	COVID-19 severe or critically	some concern	20/20	inconclusive	inconclusive 33 % decrease in mechanical ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
Li ChiCTR2000029757		RCT	convalescent plasma treatment	standard of care	COVID-19 severe or critically	some concern	52/51	inconclusive	inconclusive 40 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
PlasmAr NCT04344535		RCT	convalescent plasma treatment	placebo	COVID-19 severe or critically	low	228/106	inconclusive	inconclusive 19 % decrease in clinical improvement (PE) with a high degree of certainty due to low risk of bias
Rasheed		RCT	convalescent plasma treatment	standard of care	COVID-19 severe or critically	some concern	21/28	inconclusive
Tabarsi IRCT20151227025726N2		RCT	immunoglobulin therapy	standard of care	COVID-19 severe or critically	some concern	52/32	inconclusive	inconclusive 10 % increase in deaths,death D28 (PE) with a moderate degree of certainty due to some concern in risk of bias inconclusive 49 % increase in mechanical ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias inconclusive 44 % decrease in ICU admission (PE) with a moderate degree of certainty due to some concern in risk of bias
15 studies excluded by filtering options (7 RCT / 8 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 hospitalized meta-analysis

COVID 19 all comers meta-analysis

COVID-19 mild to moderate meta-analysis

COVID-19 severe or critically meta-analysis